68GaNOTA-anti-MMR-Nb for PET/CT assessment of protumorigenic macrophages in patients with solid tumors: preliminary results of a phase I clinical trial
Odrade Gondry(Vrije Universiteit Brussel), Marleen Keyaerts(Vrije Universiteit Brussel), Hendrik Everaert(Universitair Ziekenhuis Brussel), Catarina Xavier(Vrije Universiteit Brussel), Geert Raes(Vrije Universiteit Brussel), Johannes Heemskerk(Universitair Ziekenhuis Brussel), Kiavash Movahedi(Vrije Universiteit Brussel), Karine Breckpot(Vrije Universiteit Brussel), Lore Decoster(Universitair Ziekenhuis Brussel), Jo A. Van Ginderachter(Vrije Universiteit Brussel), Sandrine Aspeslagh(Universitair Ziekenhuis Brussel), Nick Devoogdt(Vrije Universiteit Brussel), Vicky Caveliers(Vrije Universiteit Brussel), Bart Neyns(Molecular Oncology (United States)), Tony Lahoutte(Citrix (Switzerland)), Ilse Vaneycken(Universitair Ziekenhuis Brussel), Denis Schallier(Universitair Ziekenhuis Brussel), Christel Fontaine(Universitair Ziekenhuis Brussel), Sofie Joris(Universitair Ziekenhuis Brussel)
Unknown
August 25, 2020
Cited by 1
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
|Nature Neuroscience|2021|659
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
|Annals of Oncology|2022|253